CMS Seeks Public Input on Medicare Drug Price Negotiation Information Collection
May 13, 2025
May 13, 2025
WASHINGTON, May 13 (TNSFRinfo) -- The U.S. Department of Health and Human Services Centers for Medicare & Medicaid Services (CMS) has announced a public comment period for its proposed information collection activities related to the Medicare Drug Price Negotiation Program.
This collection aims to gather necessary information for the Small Biotech Exception, the Biosimilar Delay, and the Selection of Renegotiation-Eligible Drugs for the initial price applicability year 2028, as . . .
This collection aims to gather necessary information for the Small Biotech Exception, the Biosimilar Delay, and the Selection of Renegotiation-Eligible Drugs for the initial price applicability year 2028, as . . .